Drug intelligence / Profile preview

Program 3 (Actio Biosciences)

Development stage: Preclinical
Lead developer: Actio Biosciences
Modality: Small Molecules
Administration: Oral

Overview

Program 3 is an early-stage therapeutic candidate developed by Actio Biosciences as an oral small molecule for the treatment of rare genetic epilepsies and other central nervous system (CNS) disorders. As the third asset in Actio's pipeline, it is part of the company's broader strategy to translate genetic insights into precision medicines for rare diseases. While the specific biological target and mechanism of action remain undisclosed, the program is designed to address the underlying genetic drivers of neurological conditions. It is currently in the discovery and preclinical stage of development.

Beyond the preview

Go deeper on Program 3 (Actio Biosciences).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Program 3 (Actio Biosciences).

Explore the full profile